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Abstract
Background:  The  biological  recovery  of  human  skin  allografts  is  the  gold  standard  for  preserva-
tion in  Skin  Banks.  However,  there  is  no  worldwide  consensus  about  speciﬁc  allocation  criteria
for preserved  human  skin  allografts  with  living  cells.
A report  is  presented  on  the  results  of  5  years  of  experience  of  using  human  skin  allografts  in
burned patient  in  the  Skin  and  Tissue  Bank  at  Instituto  Nacional  de  Rehabilitación.
Material  and  methods: The  human  skin  allografts  were  obtained  from  multi-organ  donors,
processed  and  preserved  at  −80 ◦C  for  12  months.  Allocation  criteria  were  performed  according
to blood  type  match,  clinical  history,  and  burned  body  surface.
Results:  Up  to  now,  the  Skin  and  Tissue  Bank  at  Instituto  Nacional  de  Rehabilitación  has
2processed  and  recovered  125,000  cm of  human  skin  allografts.  It  has  performed  34  surgical
implants on  21  burned  patients.  The  average  of  burn  body  surface  was  59.2%.  More  than  two-
thirds (67.7%)  of  recipients  of  skin  allografts  were  matched  of  the  same  to  type  blood  of  the
donor, and  66.6%  survived  after  126  days  hospital  stay.
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Conclusion:  It  is  proposed  to  consider  recipient’s  blood  group  as  allocation  criteria  to  assign
tissue; and  use  human  skin  allografts  on  patiens  affected  with  burns  over  30%  of  body  surface
(according  the  ‘‘rule  of  the  9’’).
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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El  uso  clínico  de  aloinjertos  de  piel  humana  criopreservados  con  ﬁnes  de  trasplante
Resumen
Antecedentes:  La  recuperación  biológica  de  aloinjertos  de  piel  humana  se  considera  que  es  el
estándar de  oro  para  los  procesos  de  preservación  de  bancos  de  tejidos;  sin  embargo,  no  existen
criterios de  asignación  para  los  aloinjertos  de  piel  con  elementos  celulares  vivos.
Reportamos  la  experiencia  de  5  an˜os  en  el  uso  de  aloinjertos  de  piel  humana  en  pacientes
adultos quemados,  del  Banco  de  Piel  y  Tejidos,  del  Instituto  Nacional  de  Rehabilitación.
Materiales  y  métodos: Los  aloinjertos  de  piel  humana  fueron  obtenidos  a  partir  de  donadores
multiorgánicos,  procesados  y  preservados  en  congelación  a  −80 ◦C  durante  12  meses.  La  asig-
nación de  los  aloinjertos  se  realizó  en  referencia  al  grupo  sanguíneo,  historia  clínica,  grado  de
la quemadura,  y  la  extensión  con  un  promedio  de  40%  de  superﬁcie  corporal  afectada  y  con
consentimiento  informado.
Resultados:  Hasta  el  momento  el  Banco  de  Piel  y  Tejidos  ha  procesado  más  de  125,000  cm2 de
aloinjertos  de  piel  humana.  Se  han  realizado  34  implantes  quirúrgicos  en  21  pacientes  que-
mados. El  promedio  de  superﬁcie  corporal  quemada  fue  del  59.2%.  El  67.7%  de  los  receptores
de aloinjertos  de  piel  humana  tuvieron  el  mismo  grupo  sanguíneo  que  el  donante.  El  66.6%
de los  receptores  de  aloinjertos  de  piel  humana  sobrevivió  después  de  126  días  de  estancia
hospitalaria.
Conclusión:  Se  propone  considerar  el  grupo  sanguíneo  del  receptor  como  un  criterio  para  la
asignación de  tejido;  y  el  uso  de  aloinjertos  de  piel  humana  en  pacientes  con  más  del  30%  de
la superﬁcie  corporal  quemada  (de  acuerdo  a  la  «regla  de  los  9»).
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Allografts  of  skin  and  other  tissues  were  obtained  fromackground
iological  recovery  is  the  gold  standard  in  tissue  preser-
ation  processes  in  tissue  banks.1 Quality  control,  health
ertiﬁcation  and  the  biological  stability  of  allografts  for
ransportation  has  a  direct  impact  on  the  therapeutic  result
f  a  successful  tissue  implant  for  surgical  reconstruction
rocedures  or  tissue  replacement.
Over  the  past  5  years,  the  Skin  and  Tissue  Bank  at
nstituto  Nacional  de  Rehabilitación  (BPyT-INR)  has  devel-
ped  a  technological  research  programme  dedicated  to
he  recovery,  preservation  and  implantation  of  tissues  for
ransplantation,  such  as:  skin,  deep  dermis,  cardiac  valves,
endons  and  bone  tissue.  The  primary  focus  of  the  processes
s  to  keep  the  cellular  elements  of  these  alive  and  rich  in
rowth  factors.
In the  speciﬁc  case  of  human  skin  allografts,  various
reservation  processes  have  been  described,  includ-
ng  gamma  radiation  and  sterilisation  using  chemical
ethods.1,2 However,  biological  recovery  with  controlled
hemical  disinfection  has  recently  been  accepted  as  the
ethod  with  the  best  therapeutic  results.3--5 The  method
roposed  and  developed  in  the  BPyT-INR,  the  BanPiel-INR
m
i
Hethod,  is  based  on  preserving  cellular  viability  and  con-
rolled  isotonic  disinfection  in  class  100  facilities.  This
nables  allografts  of  viable  skin  to  be  obtained  for  the
urpose  of  transplantation.6 However,  there  are  no  reports
bout  the  bank’s  experience  with  regard  to  the  distribution
r  allocation  criteria  of  live  skin  allografts  in  Mexico.  From
n  immunological  perspective,  skin  recovered  from  cadav-
ric  donors  is  used  as  temporary  covering  with  no  established
llocation  criteria.
This  article  presents  the  ﬁrst  data  of  a  skin  recovery  pro-
ramme  in  the  National  Health  Hospitals  and  Institutes  of
he  Federal  System  in  Mexico,  and  the  clinical  experiences
f  recipients.
aterial and methods
onors  and  tissuesulti-organ  donors  with  the  informed  consent  of  their  fam-
lies,  in  accordance  with  the  Ley  General  de  Salud  (General
ealth  Act)  on  organ  and  tissue  donation  for  transplantation.
The  clinical  use  of  cryopreserved  human  skin  allografts  for  trans
Table  1  Inclusion  criteria  for  human  skin  allograft
donation.
Inclusion  criteria  for  skin
donation  candidates
Exclusion  criteria  for
skin  donation  candidates
Brain  death  certiﬁcation
for  cadaveric  donor  or
certiﬁed  loss  of  life
certiﬁcation
Hyperglycaemia  +  septicaemia
Negative  serology  for
human
immunodeﬁciency
virus  types  1  and  2,
hepatitis  B,  hepatitis
C,  human
lymphotropic  virus  and
luetic  reaction  a
Unknown  cause  of  death
No signiﬁcant  history  of
diseases  affecting  the
skin
History  of  drug  abuse
No uncontrolled  septic
process
Recent  tattoos,  under  3
years
No clinical  history  of
autoimmune  disease
Skin  legion  suspicious  of
neoplasia
Age range  18--75  (aged
over  75  after
evaluation)
Uncontrolled
septicaemia
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The  protocol  for  harvesting  tissues  was  authorised  by  the
Internal  Research  Committee  of  the  Instituto  Nacional  de
Rehabilitación  (Registration  number  INR-CII-14B-2011)  and
funded  by  the  programme  of  the  Fondos  Sectoriales  de  Inves-
tigación  en  Salud  (Sector  Funds  for  Health  Research)  (Fosis
Project:  2011-161624)  as  a  multi-centre  programme  of  hos-
pitals  generating  organs  and  tissues  for  transplantation.
The  inclusion  criteria  for  skin  donation  are  summarised
in  Table  1,  and  the  current  criteria  of  the  European  Associ-
ation  of  Tissue  Banks  were  used.  The  epidemiological  data
of  all  the  donors  were  recorded,  such  as:  age,  gender,  blood
groups,  Rh  factor,  time  of  aortic  clamping  in  order  to  docu-
ment  the  warm  ischaemia  time.
Surgical  harvesting  of  skin  allografts
The  skin  and  tissues  were  harvested  in  the  operating  theatre
immediately  after  organs  were  harvested  for  transplanta-
tion.  After  the  surfaces  were  decontaminated  for  30  min
and  sterile  drapes  placed,  skin  allografts  were  ablated  of
medium  thickness  (0.5  mm/7.5  cm  wide),  with  dermatome
(Acculan  TIIIi,  B  Braun-Aesculap,  Germany).  The  sheets  of
skin  were  kept  in  washing  solution  (Sol  *BPYT-1,  pH  7.5)  for
30  min  and  then  placed  in  transport  medium  (Sol  *BPYT-2-
Piel)  with  antibiotic--antimycotic  (PPA  Biotech,  USA).Storage  in  the  BPyT
Once  the  tissue  had  been  registered  in  the  BPyT,  the  pro-
cess  of  biological  skin  recovery  took  place  according  to
T
d
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he  protocol,6 and  our  facilities’  standard  Process  Manual
PR-DQ17-ISO-9001-2008)  certiﬁed  2012,  and  with  health
icence  14TR090120006.7 The  skin  allografts  were  processed
ccording  to  the  routine  protocol  in  the  BPyT-INR,  and  were
rozen  at  −80 ◦C  in  cryopreservation  solution  (*Sol  Cryo-
iel).  All  the  tissues  were  kept  in  quarantine  until  they  were
icrobiologically,  and  health  certiﬁed  for  use.  The  qual-
ty  control  certiﬁcates  were  issued  to  document  bacterial
rowth,  absence  of  human  immunodeﬁciency  virus  type  1
nd  2  (HIV-1,  and  2),  cytomegalovirus,  hepatitis  virus  B  and
,  and  Treponema  pallidum.  Identiﬁcation  of  pathogens  was
ased  on  nucleic  acid  tests  (NATS),  in  real  time  modality
RT-PCR),  using  the  protocols  recommended  by  the  manufac-
urer  on  the  Rotor  Gene  3000  platform  (Corbett  Research,
ustralia).
eneral  skin  allograft  allocation  criteria
he  criteria  for  allocating  tissues  for  burn  patients  are  based
n  the  general  organ  allocation  criteria.  Each  patient  was
ocumented  with:  (1)  signed  informed  consent  for  the  use
f  an  allograft,  with  live  cellular  elements;  (2)  request
uthorised  by  the  manager  of  the  burns  unit,  specifying  the
ecipient’s  blood  group  and  the  volume  requested,  and  (3)
linical  history  of  the  recipient.
The  following  were  considered  speciﬁc  criteria  for  the
llocation  of  human  skin  allografts:  (1)  compatibility  with
he  recipient’s  blood  group,  (2)  degree  of  burn  and  burned
ody  surface  area,  and  (3)  the  presence  of  associated  sur-
ace  infection.
efrosting  skin  allografts
fter  the  clinical  history  and  the  allograft  request  were
eceived,  gradual  defrosting  was  scheduled  of  the  human
kin  allografts  in  sterile  conditions  and  laminar  ﬂow  hood
Herasafe  120,  Kendro;  Germany).  Once  the  tissues  had  been
efrosted  they  were  kept  in  a  phosphate  buffered  saline
olution  (PBS-pH  7.5),  with  an  antibiotic  cocktail,  taken  from
ach  recipient’s  individual  regimen.  In  this  last  point,  micro-
iological  control  samples  were  taken,  to  certify  the  tissue
efrosting  process,  and  to  rule  out  any  contamination  pro-
ess  of  the  tissue.
onitoring  of  recipient  patients
he  patients  who  had  received  grafts  were  clinically  moni-
ored  in  the  burns  intensive  care  unit.  The  clinical  course
nd  hospital  stay  of  each  of  the  recipients  was  docu-
ented.  The  recipients  were  followed  up  as  outpatients
very  6  months,  in  order  to  assess  the  implant  areas  long
erm.
ata  analysishe  data  were  gathered  on  an  Excel  MS-Ofﬁce  matrix  and
escriptive  analysis  measures  were  analysed  to  understand
he  recipient  population.
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Figure  1  Volume  of  skin  processed  in  the  Skin  and  Tissue  Bank
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time  the  allografts  were  applied.  The  frequency  of  microor-
ganisms  is  shown  in  Table  2.
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Recipients (2011-1st half 2014)
Age range (years)  1-52 Year.  
Mean : 25 Year.t Instituto  Nacional  de  Rehabilitación.
esults
olume  of  skin  processed  using  the  method  of  the
kin and  Tissue  Bank  at  Instituto  Nacional  de
ehabilitación
uring  the  period  between  1  January  2009  and  31  Decem-
er  2014,  140,351  cm2 of  human  skin  allografts,  of  medium
hickness  (0.5  mm)  were  harvested,  recovered  and  frozen  in
ur  facilities.  Quantitative  measures  were  used  for  the  pre-
iminary  analysis  of  cell  viability,  based  on  the  metabolism  of
ital  insoluble  ﬂuorophores  per  cm2 of  each  batch  of  sheets,
hich  demonstrated  the  presence  of  live  cells  in  all  the
issue,  in  a  percentage  greater  than  75%.  The  processing
olume  of  human  skin  allografts  per  year  is  illustrated  in
ig.  1,  which  shows  a  volume  in  2009  of  1923  cm2,  4825  cm2
n  2010,  6281  cm2 in  2011,  23,941  cm2 in  2012,  40,828  cm2
n  2013,  and  62,553  cm2 in  2014.
ecipients  of  human  skin  allografts  preserved  in
he Skin  and  Tissue  Bank  at  Instituto  Nacional  de
ehabilitación
uring  the  abovementioned  period,  a  total  of  34  requests
ere  received  for  tissues  with  a  range  of  238--6000  cm2,
nd  requests  were  received  for  a  total  of  57,937.5  cm2 of
kin.  The  distribution  by  institution  was  97.1%  in  the  Centro
acional  de  Atención  a  Quemados  (CENIAQ)  (National  Burns
entre),  and  2.9%  in  the  Plastic  Surgery  Department  at  Hos-
ital  General  de  México.  Allocations  of  human  skin  allografts
or  surgical  implant  were  made  from  2011,  and  were:  6  in
011,  4  in  2012,  17  in  2013,  and  7  in  the  ﬁrst  half  of  2014
Fig.  2).
pidemiological  characteristics  of  human  skin
llograft recipients
f  the  total  number  of  recipients  (n  =  21),  the  age  range  was
rom  1  to  52,  with  a  mean  age  of  25  and  a mode  of  29  (Fig.  3).
istribution  by  gender  was  44.2%  for  female  recipients  and
5.8%  for  male  recipients.igure  2  Number  of  surgical  human  skin  allograft  implants
reserved  in  the  Skin  and  Tissue  Bank.
issue  distribution  based  on  blood  group  and  Rh
actor
aking  blood  group  and  Rh  factor  as  allocation  criteria,  there
ere  34  requests  in  total,  of  those  23  were  of  the  same
lood  group  (68%),  10  requests  were  compatible  (29%)  and
ne  request  was  not  compatible  with  the  Rh  factor  (3%)
Fig.  4).
istribution  of  tissue  based  on  diagnosis  and  the
atient’s burned  body  surface  area
he  most  common  diagnoses  for  admission  to  the  human
kin  allograft  distribution  were  burns  caused  by  direct  ﬂame
6.1%  (n  =  16),  14.5%  (n  =  3)  scalds,  and  the  remaining  9.4%
ther  burns.  The  distribution  of  human  skin  allografts  in  rela-
ion  to  recipients  with  large  burned  body  surface  area  was  as
ollows:  21  patients  (range  from  29%  to  86%  of  burned  body
urface  area)  with  a  mean  of  56.4%  of  burned  body  surface
rea,  and  a  mode  of  60%  of  burned  body  surface  area  (Fig.  5).
dentiﬁcation  of  surface  microorganisms  in  the
uman skin  allograft  recipients
t  was  found  that  66.6%  (n  =  21)  of  the  recipients  were
eported  as  colonised,  and  33.4%  were  not  colonised  at  the: Mode 29 Year.
Figure  3  Age  distribution  of  human  skin  allograft  recipients.
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Figure  4  Graph  of  human  skin  allograft  allocation  by  blood  group.
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Figure  5  Distribution  of  human  skin  allografts  and  the  burned
body surface  area  of  the  recipient.  BBSA,  burned  body  surface
area.
Table  2  Microorganisms  identiﬁed  in  the  human  skin  allo-
graft recipients.
Microorganism
identiﬁed
Release
number
Frequency
percentage  (%)
Pseudomona  sp. 10  25
Acynetobacter  sp.  5  12
Candida  sp. 5  12
Staphylococcus
aureus
2  5
Acynetobacter
baumani
2 5
Did not  develop  7  17
Clinical  course  of  the  human  skin  allograft
recipients
During  monitoring  of  the  human  skin  allograft  recipients,
their  clinical  course  was  recorded  as  well  as  a  physical
assessment  of  the  grafts.  It  was  found  that  76.1%  of  the
human  skin  allograft  recipients  (n  =  14)  were  alive  one  month
after  the  human  skin  allograft  was  applied.  And  23.9%  (n  =  8)
died  during  the  ﬁrst  month  after  application  of  the  allograft
(Table  3).
Discussion
Since  it  was  founded  in  2009,  BPyT-INR  has  been  the  ﬁrst  to
propose  a  recovery  programme  for  tissues  for  transplanta-
tion.  This  programme  is  based  on  applied  research  processes
towards  meeting  health  needs.  To  date,  the  preliminary
studies  undertaken  in  a  sample  taken  at  random  from  each
tissue  batch  have  shown  a  range  of  75--85%  of  live  cells
per  cm2 of  human  skin  allograft,  with  negative  molecu-
lar  certiﬁcate  and  with  negative  microbiological  cultures,
which  are  essential  as  quality  processes  to  ensure  health
safety.  The  volume  of  processed  human  skin  allografts  has
increased  annually,  showing  an  upward  trend  for  the  period
from  2009  to  2014  (Fig.  1).  This  growth  trend  could  be  due  to
Table  3  Clinical  course  of  the  human  skin  allograft
recipients.
Number  of
patients
Mean  burned
body  surface
area  (%)
Range  of  burned
body  surface
area  (%)
Alive  n  =  14  50.07  29--83
Dead n  =  8  66.75  40--86
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 factors:  (1)  the  increase  in  the  number  of  donations  as  a
esult  of  the  impact  of  promotion  and  education  in  encour-
ging  a  culture  of  skin  and  other  tissue  donation,  which
id  not  exist  in  our  country  until  2010  when  the  BPyT-INR
aunched  their  ﬁrst  skin  donation  campaign  aimed  at  the
eneral  public  via  the  mass  media:  television,  radio,  writ-
en  press  and  the  internet,  and  (2)  the  increased  number  of
ospitals  generating  and  harvesting  tissues  in  the  national
ealth  institutes  and  other  organ  and  tissue  donation  pro-
rammes,  as  well  as  the  participation  of  other  institutions,
uch  as  the  Instituto  Mexicano  del  Seguro  Social  (IMSS),  and
he  Instituto  de  Seguridad  y  Servicios  Sociales  de  los  Traba-
adores  del  Estado  (ISSSTE),  and  the  incorporation  of  other
tate  hospitals.
he  clinical  impact  of  human  skin  allografts  for
ransplantation
uman  skin  allograft  implantation  in  burn  patients  is  the
reatment  of  choice  in  the  ﬁrst  48  h  after  their  accident8;
owever,  other  groups  of  researchers  have  described,  in
ddition  to  its  successful  use,  adding  an  individual  antibiotic
egime  in  patients  with  added  infections.
Of  the  14,100  burn  accidents  per  year,  10%  are  classi-
ed  as  major  burns,  with  third-degree  burns,  and  affected
ody  surface  area  over  30%.  The  2  age  groups  most  affected
re  children  under  10,  and  adults  over  60  with  some  form
f  disability.  It  is  interesting  that  our  data  showed  a  mode
ge  of  30  for  tissue  recipients,  which  implies  that  an  eco-
omically  active  group  is  affected.  Furthermore,  there  has
een  an  upward  trend  in  the  use  of  human  skin  allografts
hich  increased  signiﬁcantly  in  2013.  This  information  is
mportant  because  the  application  of  human  allografts  is
 relatively  new  technique  in  Mexico;  historically  pig  skin,
mnion  and  irradiated  skin  were  used  for  the  treatment  of
urn  patients.9--11 Our  results  show  that  the  application  of
uman  skin  allografts  in  burn  patients  started  in  2011,  and
eached  its  peak  of  47.2%  in  2013.
The  chief  consumer  of  human  skin  allografts  is  the  Centro
acional  de  Investigación  y  Atención  a  Quemados  (CENIAQ),
ith  97.1%  of  the  57,937.5  cm2 of  human  skin  allografts,
equested  in  the  period  from  2011  to  2014.  This  increase
s  explained  by  the  fortuitous  national  contingency  situa-
ion  in  2013,  and  because  the  main  consumer  of  tissues  was
 national  reference  centre  (CENIAQ).  However,  the  alloca-
ion  of  tissues  is  limited  to  burns  units  of  hospitals  which
ave  valid  permission  for  organ  and/or  tissue  donation  or
ransplantation  granted  by  COFEPRIS.  This  situation  should
e  assessed  according  to  Mexico’s  current  legislation,  with-
ut  forgetting  that  the  method  for  the  biological  recovery
f  tissues  involves  the  risk  of  transmitting  infectocontagious
iseases,  which  can  be  identiﬁed  with  high  sensitivity  molec-
lar  tests,  such  as  NATS,12--14 in  order  to  minimise  the  risk  of
ransmission;  we  have  implemented  these  in  our  processes
ince  the  beginning  of  the  programme.7,15,16
The  most  frequent  recipients  of  human  skin  allografts
re  men  in  the  third  decade  of  life,  who  have  had  a
uman  skin  allograft  implanted  surgically,  with  a  mean
ody  surface  area  of  59.2%  of  burned  body  surface  area
Fig.  5).  This  information  is  consistent  with  that  reported
n  the  literature,  and  reafﬁrms  the  use  of  human  skin
C
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llografts  in  major  burns  patients  as  the  treatment  of
hoice.
he  allocation  of  human  skin  allografts  based  on
lood group
ccording  to  the  reports  in  the  literature,  there  is  no  consen-
us  at  all  with  regard  to  taking  blood  type  (ABO  system  and
h  factor)  into  consideration  when  allocating  human  skin
llografts,  because  they  are  considered  temporary  cover-
ngs.  In  this  report,  68%  of  requests  were  made  according
o  the  recipient’s  blood  group,  29%  were  for  compatible
roups;  and  there  was  only  one  case  where  an  incompati-
le  group  was  designated  (Fig.  4),  a  different  blood  group
as  used  in  the  latter  case,  because  the  recipient  had  a  rare
lood  type  (A  Rh  negative).  The  reason  for  taking  this  refer-
nce  as  an  allocation  criterion  is  based  on  the  fact  that  the
raditional  processing  methods,  such  as  gamma  radiation  or
hemical  sterilisation,  although  demonstrated  as  safe  proce-
ures,  have  the  disadvantage  that  cell  viability  is  sacriﬁced.
onsidering  that  the  method  we  use  in  our  bank  is  biological
ecovery,  this  factor  could  be  essential  in  implementing  sci-
ntiﬁcally  based  use  of  human  skin  allografts  according  to
he  recipients’  blood  group,  in  order  to  minimise  responses
f  incipient  graft  rejection.
It  was  found  that  67%  of  the  human  skin  allograft  recipi-
nts  were  alive  after  discharge  from  hospital.  And  32.3%  of
he  human  skin  allograft  recipients  died  during  the  course  of
heir  medical  treatment.  The  burned  body  surface  area  of
he  surviving  patients  had  a  lower  mean  rate  (50.07%  burned
ody  surface  area)  compared  with  the  group  of  patients  who
ied  (66.75%  burned  body  surface  area).  This  suggests  that
atients  with  greater  burned  body  surface  area  present  a
reater  risk  of  death.  However,  a more  detailed  analysis  is
ecessary  of  the  conditions  of  the  recipients,  their  clinical
ourse,  and  their  general  condition  on  receiving  the  implant,
nd  the  presence  of  superimposed  infections,  since  these
actors  are  essential  and  decisive  for  prognosis.
onclusions
ccording  to  our  preliminary  results,  the  human  skin  allo-
rafts  processed  in  our  bank  are  of  high  biological  quality
nd  highly  safe,  which  means  that  they  can  be  used  safely
n  major  burns  patients.  Considering  that  the  major  burns
atient  is  kept  immunosupressed,  and  even  when  there  is  no
onsensus  on  the  use  of  human  skin  allografts  for  transplan-
ation,  it  is  suggested  that  the  blood  type  of  the  recipient
hould  be  taken  as  a criterion  for  tissue  allocation,  based
n  the  presence  of  live  elements  in  tissues  processed  by
iological  recovery.  A  more  detailed  medium  and  long-term
ollow-up  study  is  necessary  to  determine  the  impact  of  the
se  of  human  skin  allografts  in  major  burns  patients  in  order
o  establish  their  therapeutic  efﬁcacy,  and  the  economic
epercussions  for  the  national  health  system.onﬂict of interests
he  authors  have  no  conﬂict  of  interests  to  declare.
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